What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2023-03-14 compared with 2022-04-06 · 17 added, 29 removed, 10 unchanged (82% of the section changed)

1 unchanged sentence

for Common Equity

common stock is traded on the Nasdaq Capital Market under the symbol “LUCD”.

of March 29, 2022, there were 37,432,536 shares of our common stock issued (inclusive of shares of common stock underlying

unvested restricted stock awards granted under the Lucid Diagnostics Inc.

2018 Long-Term Incentive Equity Plan).

shares of common stock are held by an estimated 13 holders of record and we believe our shares of common stock are held

by more than beneficial owners.

common stock is traded on the Nasdaq Global Market under the symbol “LUCD”.

As of March 9, 2023, there were 43,393,716 shares of our common stock

Our shares of common stock are held by an estimated 19 holders of record and we believe our shares of common stock are held

by significantly more beneficial owners.

have not paid any cash dividends on our common stock to date.

6 unchanged sentences

Sales of Unregistered Securities and Use of Proceeds

as previously disclosed in our current reports on Form 8-K and quarterly reports on Form 10-Q, and except as disclosed below,

we did not sell any unregistered securities or repurchase any of our securities during the fiscal year ended December 31, 2021.

October 14, 2021, we completed our IPO of our common stock under an effective registration statement on Form S-1 (SEC File No.

Cantor and Cannacord Genuity served as joint bookrunning managers of the IPO.

In our IPO, we sold a total of 5.0 million shares of our

common stock, inclusive of 571,428 shares sold to PAVmed, at a public offering price of $14.00 per share, resulting in gross proceeds

of $70.0 million and net proceeds of 64.4, after deducting underwriting fees of $4.9 million and approximately $0.7 million of offering

costs incurred by us.

None of the fees and expenses of the IPO were paid to any of our directors, officers, 10% stockholders, or affiliates.

December 31, 2021, of the net proceeds of $64.4 million, approximately $10.7 million has been used, in a manner consistent with the

use of proceeds set forth in the prospectus for our IPO, as follows:

at total of approximately $3.3 million of repayments of Due To:

PAVmed Inc., inclusive of:

Management Services Agreement fee (“MSA Fee”) of $2.3 million;

operating expenses paid by

on-behalf-of the Company of approximately $0.3 million;

and the payment of interest expense of the Senior Unsecured

Promissory Note dated June 1, 2021;

and approximately $0.8 million for the purchase of equipment;

and $6.7 million of working

capital expenditures.

None of the proceeds have been paid to any of our directors, officers, 10% stockholders, or affiliates, other

than as described above.

as previously disclosed in our current reports on Form 8-K and quarterly reports on Form 10-Q, and except as disclosed below, we did

not sell any unregistered securities or repurchase any of our securities during the fiscal year ended December 31, 2022.

October 14, 2021, we completed our initial public offering (“IPO”) of our common stock under an effective registration statement

on Form S-1 (SEC File No.

As of December 31, 2022, of the net proceeds of $64.4 million, approximately $43.7 million has

been used, in a manner consistent with the use of proceeds set forth in the prospectus for our IPO, as follows:

approximately $5.3 million

of net repayments of Due To:

approximately $5.0 million for the purchase of our laboratory equipment, software, and its

operating expenses;

and $33.4 million of working capital expenditures.

None of the proceeds have been paid to any of our directors, officers,

10% stockholders, or affiliates, other than as described above.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity